PharmaCyte Biotech Stock (NASDAQ:PMCB)


OwnershipFinancialsChart

Previous Close

$1.64

52W Range

$1.39 - $2.58

50D Avg

$1.73

200D Avg

$1.94

Market Cap

$11.15M

Avg Vol (3M)

$31.14K

Beta

-0.20

Div Yield

-

PMCB Company Profile


PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jan 02, 2013

Website

PMCB Performance


PMCB Financial Summary


Apr 23Apr 22Apr 21
Revenue---
Operating Income$-6.46M$-4.39M$-3.62M
Net Income$-4.32M$-4.09M$-3.55M
EBITDA$-4.32M$-4.24M$-3.62M
Basic EPS$-0.22$-0.26$-2.46
Diluted EPS$-0.22$-0.26$-2.46

Fiscal year ends in Apr 23 | Currency in USD

Peer Comparison


TickerCompany
YMABY-mAbs Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
SPRBSpruce Biosciences, Inc.
IVVDInvivyd, Inc.
CNTBConnect Biopharma Holdings Limited
NUVBNuvation Bio Inc.
ANTXAN2 Therapeutics, Inc.
NXTCNextCure, Inc.
MLYSMineralys Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
CSBRChampions Oncology, Inc.
PEPGPepGen Inc.
KZRKezar Life Sciences, Inc.
TILInstil Bio, Inc.
STTKShattuck Labs, Inc.
PHVSPharvaris N.V.
OVIDOvid Therapeutics Inc.
MOLNMolecular Partners AG